# EDGAR Filing Document

**Accession Number:** 0001810560
**File Stem:** 0001193125-25-277581
**Filing Date:** 2025-11
**Character Count:** 26950
**Document Hash:** 83e92712c1c65f39ecab893f96a215fd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-277581.hdr.sgml**: 20251112

**ACCESSION NUMBER**: 0001193125-25-277581

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20251112

**DATE AS OF CHANGE**: 20251112

**EFFECTIVENESS DATE**: 20251112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** REVELATION BIOSCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001810560
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 843898466
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-291467
- **FILM NUMBER:** 251472791

**BUSINESS ADDRESS:**
- **STREET 1:** 4660 LAJOLLA VILLAGE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122
- **BUSINESS PHONE:** 650-800-3717

**MAIL ADDRESS:**
- **STREET 1:** 4660 LAJOLLA VILLAGE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Petra Acquisition Inc.
- **DATE OF NAME CHANGE:** 20200423

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**REVELATION BIOSCIENCES, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **84-3898466** |
| (State or other jurisdiction of<br>incorporation or organization) | (I.R.S. Employer<br>Identification No.) |

---

**4660 La Jolla Village Drive, Suite 100**

**San Diego, CA 92122**

(Address of principal executive offices, including zip code)

**REVELATION BIOSCIENCES, INC. 2021 EQUITY INCENTIVE PLAN**

(Full title of the plan)

**James Rolke, Chief Executive Officer**

**Revelation Biosciences, Inc.**

**4660 La Jolla Village Drive, Suite 100**

**San Diego, CA 92122**

**650-800-3717**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

*Copy to:*

**Stephen M. Cohen, Esq.<br>Lauren W. Taylor, Esq.<br>Fox Rothschild LLP**

**2001 Market Street, Suite 1700** 

**Philadelphia, PA 19103**

**Telephone: 215-299-2000**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | |
|:---|:---|
| Large accelerated filer ☐ | Accelerated filer ☐ |
| Non-accelerated filer ☒ | Smaller Reporting Company ☒ |
|  | Emerging growth company ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

**Item 1. Plan Information**

This Registration Statement is being filed for the purpose of registering 4,647,222 additional shares of common stock, par value $0.001 ("Common Stock"), of Revelation Biosciences, Inc. (the "Registrant") issuable under the 2021 Equity Incentive Plan (the "Plan"). The Registrant previously filed Registration Statements on Form S-8 covering Common Stock issuable under the Plan (File Nos. 333-265329, 333-273933, and 333-280313) (the "Prior Registration Statements").

Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statements are incorporated by reference in this Registration Statement to the extent not modified or superseded hereby or by any subsequently filed document which is incorporated by reference herein or therein.

**Item 2. Registrant Information and Employee Plan Annual Information**

Upon written or oral request, any of the documents incorporated by reference in Item 3 of Part II of this registration statement (which are incorporated by reference in this Section 10(a) Prospectus) and any other documents required to be delivered to eligible employees, nonemployee directors, and consultants pursuant to Rule 428(b) are available, without charge, by contacting:

Chester S. Zygmont, III, Chief Financial Officer

Revelation Biosciences, Inc.

4660 La Jolla Village Drive, Suite 100

San Diego, California 92122

650-800-3717

------

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference**

The following documents, as filed with the SEC by Revelation Biosciences, Inc., a Delaware corporation (File No. 001-39603) (the "Company"), pursuant to the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or the Securities Act are hereby incorporated by reference:

(i) Annual Report on [<u>Form 10-K</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000095017025034584/revb-20241231.htm) for the period ended December 31, 2024, filed with the SEC on March 6, 2025 (the "Registrant Annual Report");

(ii) The Company's Current Reports on Form 8-K filed on [<u>January 7, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000095017025002828/revb-20250103.htm) , [<u>January 21, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000095017025007303/revb-20250117.htm) , [<u>January 30, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000095017025011197/revb-20250128.htm) , [<u>February 11, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000095017025017882/revb-20250210.htm) , [<u>February 24, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000095017025025626/revb-20250219.htm) , [<u>March 6, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000095017025034689/revb-20250306.htm) , [<u>March 17, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000095017025040294/revb-20250317.htm) , [<u>May 8, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000095017025067043/revb-20250508.htm) , [<u>May 28, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000095017025078340/revb-20250523.htm) , [<u>June 4, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000095017025081604/revb-20250528.htm) , [<u>June 25, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000095017025089972/revb-20250623.htm) , [<u>July 9, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000095017025094789/revb-20250707.htm) , [<u>August 8, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000095017025105485/revb-20250808.htm) , [<u>September 9, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000181056025000006/revb-20250909.htm) , [<u>September 15, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000119312525203750/revb-20250911.htm) , [<u>October 15, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000119312525240400/revb-20251015.htm) , [<u>October 29, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000119312525256367/revb-20251029.htm) , and [<u>November 6, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000119312525269450/revb-20250930.htm) ;

(iii) Quarterly Reports on Form 10-Q for the period ended [<u>March 31, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000095017025066897/revb-20250331.htm) , filed with the SEC on May 8, 2025, the period ended [<u>June 30, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000095017025105284/revb-20250630.htm) , filed with the SEC on August 8, 2025, and the period ended September 30, 2025, filed with the SEC on [<u>November 6, 2025</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000119312525269696/revb-20251106.htm) ;

(iv) All other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant Annual Report; and

(v) The description of the Company's common stock contained in its registration statement on [<u>Form S-1</u>](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001810560/000121390025047104/ea0243185-s1a1_revelation.htm) (Registration No. 333-287423) filed with the SEC on May 23, 2025.

All other documents filed by the Company with the SEC pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act after the date of this registration statement and before the filing of a post-effective amendment to this registration statement that indicate that all securities offered hereby have been sold, or that deregisters all such securities remaining unsold, will be deemed to be incorporated by reference in this registration statement and to be a part hereof from the date of filing of such documents.

**Item 4. Description of Securities**

Not applicable.

**Item 5. Interests of Names Experts and Counsel**

None.

------

**Item 6. Indemnification of Directors and Officers**

As permitted by Section 102 of the Delaware General Corporation Law, we have adopted provisions in our Third Amended and Restated Certificate of Incorporation, as amended (the "Charter") and our Second Amended and Restated Bylaws, as amended (the "Bylaws") that limit or eliminate the personal liability of our directors for a breach of their fiduciary duty of care as a director. The duty of care generally requires that, when acting on behalf of the corporation, directors exercise an informed business judgment based on all material information reasonably available to them. Consequently, a director will not be personally liable to us or our stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for:

● any breach of the director's duty of loyalty to us or our stockholders;

● any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

● any act related to unlawful stock repurchases, redemptions or other distributions or payment of dividends; or

● any transaction from which the director derived an improper personal benefit.

These limitations of liability do not affect the availability of equitable remedies such as injunctive relief or rescission. Our Charter also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law.

As permitted by Section 145 of the Delaware General Corporation Law, our Bylaws provide that:

● we may indemnify our directors, officers and employees to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions;

● we may advance expenses to our directors, officers and employees in connection with a legal proceeding to the fullest extent permitted by the Delaware General Corporation Law, subject to limited exceptions; and

● the rights provided in our amended and restated bylaws are not exclusive.

Our Charter and our Bylaws provide for the indemnification provisions described above and elsewhere herein. We have entered or will enter into, and intend to continue to enter into, separate indemnification agreements with our directors and officers that may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements generally require us, among other things, to indemnify our officers and directors against certain liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct. These indemnification agreements also generally require us to advance any expenses incurred by the directors or officers as a result of any proceeding against them as to which they could be indemnified. These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of our officers and directors for liabilities, including reimbursement of expenses incurred, arising under the Securities Act of 1933, as amended, or the Securities Act.

**Item 7. Exemption from Registration Claimed**

Not applicable.

------

**Item 8. Exhibits**

---

| | | |
|:---|:---|:---|
| **Exhibit Number** | **Title of Document** | **Location** |
| 4.1 | [<u>Common Stock Specimen</u>](https://www.sec.gov/Archives/edgar/data/1810560/000121390020019100/fs12020ex4-2_petraacq.htm) | Incorporated by reference to the Registration Statement on Form S-1 filed May 23, 2025 |
| 5.1 | [<u>Opinion of Fox Rothschild LLP</u>](revb-ex5_01.htm) | This filing |
| 10.1 | [<u>Revelation Biosciences, Inc. 2021 Equity Incentive Plan, as amended</u>](https://www.sec.gov/Archives/edgar/data/1810560/000095017024044514/2024_annual_meeting_def_.htm) | Incorporated by reference to Appendix A to the definitive proxy statement filed with the SEC on June 6, 2025 |
| 23.1 | [<u>Baker Tilly US, LLP</u>](revb-ex23_01.htm) | This filing |
| 23.2 | [<u>Consent of Fox Rothschild LLP</u>](revb-ex5_01.htm) | Included in Exhibit 5.01 |
| 24.1 | [<u>Power of Attorney</u>](#p_001) | See signature page to this filing |
| 107 | [<u>Filing Fee Table</u>](revb_exfilingfees.htm) | This filing |

---

------

**Item 9. Undertakings**

<u>Undertaking Required by Item 512(a) of Regulation S-K</u>: The undersigned registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i) To include any prospectus required by section 10(a)(3) of the Securities Act;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

<u>Undertaking Required by Item 512(b) of Regulation S-K</u>: The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to section 15(d) of the Securities Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

<u>Undertaking Required by Item 512(h) of Regulation S-K</u>: Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

------

**SIGNATURES**

Pursuant to the requirements of Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in San Diego, California, on the 12th day of November, 2025.

---

| | |
|:---|:---|
| **REVELATION BIOSCIENCES, INC.** | **REVELATION BIOSCIENCES, INC.** |
| By: | */s/ James Rolke*  |
|  | James Rolke |
|  | Chief Executive Officer |

---

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below constitutes and appoints Chester S. Zygmont, III, as his or her true and lawful attorney-in-fact, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto and all documents in connection therewith, with the SEC, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, and hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated:

---

| | | |
|:---|:---|:---|
| **Name and Signature** | **Title** | **Date** |
| */s/ James Rolke* | Chief Executive Officer and Director | November 12, 2025 |
| James Rolke |  |  |
| */s/ Chester S. Zygmont, III* | Chief Financial Officer and | November 12, 2025 |
| Chester S. Zygmont, III | Principal Accounting Officer |  |
| */s/ Jennifer Carver* | Director | November 12, 2025 |
| Jennifer Carver |  |  |
| */s/ Jess Roper* | Director | November 12, 2025 |
| Jess Roper |  |  |
| */s/ Lakhmir Chawla* | Director | November 12, 2025 |
| Lakhmir Chawla, M.D. |  |  |

---

------

## Exhibit 5.01

**Exhibit 5.01**

![img127738591_0.jpg](img127738591_0.jpg)

November 12, 2025

Revelation Biosciences, Inc.

4660 La Jolla Village Drive, Suite 100

San Diego, California 92122

**Re: Revelation Biosciences, Inc.** 

**Registration Statement on Form S-8**

Ladies and Gentlemen:

We have acted as counsel to Revelation Biosciences, Inc., a Delaware corporation (the "Company"), in connection with the Company's registration of an aggregate of 4,647,222 shares (collectively, the "Shares") of the Company's common stock, par value $0.001 per share (the "Common Stock"), issuable under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, as amended (the "Plan"), pursuant to a registration statement on Form S-8 (the "Registration Statement") under the Securities Act of 1933, as amended (the "Securities Act"), filed by the Company with the Securities and Exchange Commission (the "SEC") on November 12, 2025.

In connection with this opinion, we have examined and relied upon the originals, or copies certified or otherwise identified to our satisfaction, of such records, documents, certificates and other instruments as in our judgment are necessary or appropriate to enable us to render the opinions expressed below. As to certain factual matters, we have relied upon certificates of the officers of the Company and have not sought to independently verify such matters.

In rendering this opinion, we have assumed the genuineness and authenticity of all signatures on original documents, including electronic signatures made and/or transmitted using electronic signature technology (e.g., via DocuSign or similar electronic signature technology); that any such signed electronic record shall be valid and as effective to bind the party so signing as a paper copy bearing such party's handwritten signature; the legal capacity of all natural persons; the authenticity of all documents submitted to us as originals; the conformity to originals of all documents submitted to us as certified or photocopies; the authenticity of the originals of such latter documents; the accuracy and completeness of all documents and records reviewed by us; the accuracy, completeness and authenticity of certificates issued by any governmental official, office or agency and the absence of change in the information contained therein from the effective date of any such certificate; and other than for the Company, the due authorization, execution and delivery of all documents where authorization, execution and delivery are prerequisites to the effectiveness of such documents. We have also assumed that none of the Shares will be issued in violation of any restriction or limitation contained in the Company's charter documents or the Plan; and that upon

------

any issuance of Shares, the total number of shares of Common Stock issued and outstanding will not exceed the total number of shares of Common Stock that the Company is then authorized to issue under the Company's charter documents or the Plan.

Our opinion herein is expressed solely with respect to the General Corporation Law of the State of Delaware (including the statutory provisions, all applicable provisions of the Delaware Constitution and reported judicial decisions interpreting the foregoing) and is based on these laws as in effect on the date hereof. We express no opinion as to whether the laws of any jurisdiction are applicable to the subject matter hereof. We are not rendering any opinion as to compliance with any federal or other state law, rule or regulation relating to securities, or to the sale or issuance thereof.

On the basis of the foregoing and in reliance thereon, and subject to the qualifications herein stated, we are of the opinion that the Shares registered pursuant to the Registration Statement have been duly and validly authorized and reserved for issuance and that upon the issuance of the Shares and payment therefor in accordance with the provisions of the Plan, the Shares will be validly issued, fully paid and non-assessable.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the SEC thereunder. This opinion is expressed as of the date hereof, and we disclaim any undertaking to update or supplement this opinion or to advise you of any subsequent changes in the facts stated or assumed herein or of any subsequent changes in applicable law.

Very truly yours,

/s/ Fox Rothschild LLP

------

## Exhibit 23.01

**Exhibit 23.01**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of Revelation Biosciences, Inc. (the "Company") of our report dated March 6, 2025 relating to the consolidated financial statements of Revelation Biosciences, Inc., as of and for the years ended December 31, 2024 and 2023, which includes an explanatory paragraph regarding the existence of substantial doubt about the Company's ability to continue as a going concern, appearing in the Company's Annual Report on Form 10-K as of and for the year ended December 31, 2024.

/s/ Baker Tilly US, LLP

San Diego, California

November 12, 2025

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

**Exhibit 107**

**Calculation of** Filing Fee **Tables** 

FORM S-8

(Form Type)

REVELATION BIOSCIENCES, INC.

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | Security<br>Type | Security<br>Class<br>Title | Fee<br>Calculation<br>or Carry<br>Forward<br>Rule | Proposed<br>Maximum<br>Offering<br>Price Per<br>Unit | Maximum<br>Aggregate<br>Offering<br>Price<sup>(2)</sup> | Fee<br>Rate | Amount of<br>Registration<br>Fee |
| Fees to Be<br>Paid<br>| Equity | Shares of Common Stock, par value $0.001 per share ("Common Stock")  | 457(c) and 457(h)<br>4647222<sup>(3)</sup> | $1.01 | $4693694.22 | 0.0001381 | $648.20 |
| Total Offering Amounts  | Total Offering Amounts  | Total Offering Amounts  | Total Offering Amounts  |  | $4693694.22 |  | $648.20 |
| Total Fee Offsets<sup>(4)</sup> | Total Fee Offsets<sup>(4)</sup> | Total Fee Offsets<sup>(4)</sup> | Total Fee Offsets<sup>(4)</sup> |  |  |  | – |
| Net Fee Due | Net Fee Due | Net Fee Due | Net Fee Due |  |  |  | $648.20 |

---

(1) Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended, or the Securities Act, this Registration Statement shall also cover any additional shares of Registrant's Common Stock that become issuable under the plans set forth herein by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Registrant's Common Stock, as applicable.

(2) Estimated in accordance with Rules 457(c) and 457(h) solely for the purpose of calculating the registration fee on the basis of $1.01 per share, the closing price of the Registrant's Common Stock on November 6, 2025, as reported on the Nasdaq Global Select Market.

(3) Represents an increase of 4,647,222 shares of the Registrant's Common Stock available for grant under the 2021 Equity Plan.

(4) The registrant does not have any fee offsets.

------